Ropivakain Sintetica: Uses, Dosage & Side Effects
A long-acting amide-type local anesthetic containing ropivacaine hydrochloride 2 mg/ml, used for continuous epidural infusion and peripheral nerve block in acute pain management, including postoperative analgesia and labor pain
Ropivakain Sintetica (ropivacaine hydrochloride 2 mg/ml) is a long-acting amide-type local anesthetic administered into the epidural space or around peripheral nerves to produce regional analgesia. At this low concentration (0.2%), ropivacaine preferentially blocks pain-carrying sensory nerve fibers while largely sparing motor fibers, making it the anesthetic of choice for continuous epidural infusions during labor and after major surgery. This medication is administered only by qualified anesthesiologists or specifically trained healthcare professionals in a hospital or clinical setting with full resuscitation equipment immediately available.
Quick Facts About Ropivakain Sintetica
Key Takeaways
- Ropivakain Sintetica contains ropivacaine hydrochloride 2 mg/ml (0.2%), a long-acting amide-type local anesthetic used for continuous epidural infusion, continuous peripheral nerve block, and field block in acute pain management.
- Ropivacaine is the pure S-enantiomer of a chemically related pair of stereoisomers and is associated with a more favorable cardiac safety profile than racemic bupivacaine at equipotent doses.
- At the 2 mg/ml strength, ropivacaine produces effective sensory blockade with minimal motor impairment — a property clinically known as "differential block" that enables ambulatory epidural analgesia during labor and early mobilization after surgery.
- The medication must never be administered by intravenous regional (Bier block) route or by obstetric paracervical injection. It is also contraindicated in patients with known hypersensitivity to amide-type local anesthetics and in general contraindications to regional anesthesia.
- Administration must be carried out only by healthcare professionals experienced in regional anesthesia, with continuous patient monitoring and immediate access to resuscitation equipment and 20% lipid emulsion for treatment of local anesthetic systemic toxicity (LAST).
What Is Ropivakain Sintetica and What Is It Used For?
Quick Answer: Ropivakain Sintetica is a sterile, preservative-free 2 mg/ml solution of ropivacaine hydrochloride for infusion into the epidural space or around peripheral nerves. It is used for acute pain management — including continuous epidural analgesia for postoperative pain and labor pain, and continuous peripheral nerve block after major orthopedic and general surgery — as well as for field block and, in some protocols, infiltration analgesia.
Ropivakain Sintetica belongs to the class of medicines known as amide-type local anesthetics. The active substance, ropivacaine, is structurally related to bupivacaine and mepivacaine but differs in a clinically important way: it is supplied as the pure S-enantiomer, which binds less avidly to cardiac sodium channels than the racemic mixture of bupivacaine. This stereochemical difference translates into a wider margin of safety for cardiovascular and central nervous system toxicity, which is especially relevant when large volumes of local anesthetic are infused continuously over many hours.
Ropivacaine works by reversibly blocking voltage-gated sodium channels in the membranes of nerve cells. Sodium channel opening is the first step in generating and propagating an action potential; by blocking them, ropivacaine prevents both the initiation and the transmission of nerve impulses. Sensory fibers that carry pain signals are smaller and more susceptible to this blockade than the larger, heavily myelinated motor fibers. At a low concentration such as 2 mg/ml, ropivacaine can therefore produce profound analgesia while leaving motor function largely intact — a property known as "differential" or "preferential" sensory block.
The 2 mg/ml strength of ropivacaine has a wide range of clinical applications. In obstetric practice, it is the cornerstone of modern epidural labor analgesia: infused at 6–14 ml per hour (often combined with a small dose of a lipophilic opioid such as fentanyl or sufentanil), it provides continuous pain relief throughout labor while preserving enough motor function to allow supported ambulation in selected patients. In postoperative care, it is delivered as a continuous epidural infusion or as a continuous perineural infusion through a catheter placed adjacent to a peripheral nerve or plexus (for example, brachial plexus, femoral nerve, or sciatic nerve), providing days of effective analgesia after major orthopedic, thoracic, or abdominal procedures. It is also used for intermittent bolus top-ups via an epidural or peripheral nerve catheter.
Ropivacaine was first approved by the European Medicines Agency and the U.S. Food and Drug Administration in the mid-1990s and has since become one of the most widely used long-acting local anesthetics worldwide. It is included in the World Health Organization's Model List of Essential Medicines as a representative long-acting local anesthetic for regional anesthesia. Ropivakain Sintetica is a specific branded formulation manufactured by Sintetica SA and is marketed in several European countries.
Higher concentrations of ropivacaine (7.5 mg/ml and 10 mg/ml) are used for surgical anesthesia, where dense sensory and motor block is required. The 2 mg/ml concentration described on this page is reserved for analgesia (pain relief) rather than surgical anesthesia, because at this dilution the motor block is generally insufficient to permit surgical intervention. Your anesthesiologist will choose the concentration and technique best suited to your clinical situation.
What Should You Know Before Receiving Ropivakain Sintetica?
Quick Answer: Ropivakain Sintetica must not be used in patients with known hypersensitivity to amide-type local anesthetics or to any of its excipients, and it must never be given by intravenous regional anesthesia (Bier block) or for obstetric paracervical anesthesia. Several medical conditions — including severe heart disease, hypovolemia, infection at the injection site, and coagulopathy — require particular caution. Tell your anesthesiologist about all medications, supplements, and conditions before administration.
Contraindications
Ropivakain Sintetica is contraindicated and must not be used in the following situations:
- Hypersensitivity: Known allergy to ropivacaine, to any other amide-type local anesthetic, or to any of the excipients (sodium chloride, sodium hydroxide or hydrochloric acid for pH adjustment, water for injections).
- Intravenous regional anesthesia (Bier block): Ropivacaine must never be used in this technique because of the high risk of systemic toxicity should tourniquet failure release the entire dose rapidly into the circulation.
- Obstetric paracervical anesthesia: Use of amide-type local anesthetics in paracervical block during labor has been associated with fetal bradycardia and is contraindicated.
- General contraindications to regional anesthesia: Active infection at or near the planned injection site, severe coagulopathy, therapeutic anticoagulation incompatible with current neuraxial guidelines, severe hypovolemia, raised intracranial pressure, or patient refusal.
Warnings and Precautions
Before receiving ropivacaine, inform your anesthesiologist if any of the following apply:
- Previous adverse or allergic reaction to any local anesthetic
- Significant heart disease, including arrhythmias, advanced atrioventricular block, ischemic heart disease, or heart failure
- Severe liver disease, as ropivacaine is primarily metabolized by the liver (CYP1A2 and CYP3A4)
- Severe kidney disease, especially with concurrent acidosis
- Low blood volume (hypovolemia), dehydration, or uncontrolled bleeding
- Known or suspected acute porphyria — ropivacaine is considered unsafe in porphyria and alternative agents should be considered
- Neurological diseases, including multiple sclerosis, hemiplegia, paraplegia, or neuromuscular disorders
- Pre-existing spinal deformity, previous spinal surgery, or infection near the proposed puncture site
- Use of anticoagulant or antiplatelet medications (follow ESRA/ASRA guidelines for neuraxial procedures)
- Elderly age or generally poor physical condition (higher risk of hemodynamic instability)
Regional anesthetic procedures with Ropivakain Sintetica must be performed only by clinicians with the appropriate training, experience, and credentials. The responsible physician must be able to diagnose and treat any adverse reaction that may arise, including systemic local anesthetic toxicity and high or total spinal block. Oxygen, suction, airway equipment, emergency medications, and 20% intravenous lipid emulsion must be immediately available in the procedure and recovery areas.
Careful aspiration before and during all injections is essential to minimize the risk of inadvertent intravascular injection. For epidural anesthesia, a small test dose (often including adrenaline) is usually administered first to detect accidental intravascular or intrathecal placement of the catheter. The patient should be monitored continuously during infusion, including heart rate, blood pressure, oxygen saturation, and level of consciousness, especially during the initial hours and after any bolus dose.
Even with careful technique, there is a small but real risk of local anesthetic systemic toxicity (LAST), which can manifest as central nervous system excitation (numb lips, metallic taste, tinnitus, agitation, seizures) followed by cardiovascular depression (hypotension, arrhythmias, cardiac arrest). Although ropivacaine has a better cardiac safety profile than racemic bupivacaine, LAST remains a life-threatening emergency. Immediate availability of 20% lipid emulsion and a trained team familiar with current ASRA/ESRA LAST management guidelines is mandatory.
Pregnancy and Breastfeeding
Extensive clinical experience supports the use of ropivacaine at recommended doses for obstetric analgesia, including during labor and for cesarean delivery when appropriate concentrations are used. Ropivacaine crosses the placenta, but protein binding in both maternal and fetal plasma limits the amount of free drug reaching the fetus. No teratogenic effects have been identified in animal studies at therapeutic doses, and no pattern of congenital abnormalities has been identified in humans. Nevertheless, as with any medicine used in pregnancy, ropivacaine should only be used when the expected benefit outweighs any potential risk, a judgment best made by the attending anesthesiologist and obstetrician.
Ropivacaine is secreted in breast milk in very small amounts, and nursing is not contraindicated after regional anesthesia with recommended doses. The amount of drug potentially ingested by a breastfed infant is well below any concentration considered pharmacologically active. Breastfeeding can normally resume as soon as the mother is alert and comfortable following the procedure.
Driving and Using Machines
Ropivakain Sintetica affects the ability to drive and operate machinery. Besides any direct neurological effects, the regional block itself can produce lingering numbness or weakness in the legs that makes driving unsafe. Patients should not drive, operate heavy machinery, or make important decisions for at least 24 hours after a significant regional block, or until the responsible clinician has confirmed that all effects of the anesthetic and any co-administered sedatives or opioids have resolved.
Ropivakain Sintetica 2 mg/ml contains approximately 3.4 mg of sodium per ml. For a typical continuous epidural infusion at 10 ml/hour, this amounts to around 34 mg of sodium per hour (approximately 1.5 mmol/hour). This should be considered in patients on a strict sodium-restricted diet, particularly those with severe heart failure or advanced renal disease.
How Does Ropivakain Sintetica Interact with Other Drugs?
Quick Answer: Ropivacaine interacts with strong CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin), which can significantly raise plasma concentrations, as well as with other local anesthetics and class I/III antiarrhythmic agents (e.g., lidocaine, amiodarone) due to additive cardiac effects. Tell your anesthesiologist about every medication, supplement, and herbal product you take, even if taken only occasionally.
Most drug interactions with ropivacaine arise through one of three mechanisms: altered hepatic metabolism (especially via the cytochrome P450 1A2 pathway), additive pharmacodynamic effects on the heart or central nervous system, or competitive effects on sodium channels and conduction. Because Ropivakain Sintetica is given in a controlled setting by an anesthesiologist, most interactions can be anticipated and managed, but a complete medication history remains essential.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustment, an alternative anesthetic strategy, or enhanced monitoring:
| Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Strong CYP1A2 Inhibitors (e.g., fluvoxamine, enoxacin) | Inhibit hepatic metabolism of ropivacaine, reducing clearance by up to 70% | Markedly increased plasma ropivacaine concentrations; increased risk of systemic toxicity | Avoid combination when prolonged infusion is planned, or reduce ropivacaine dose and monitor plasma levels |
| Other Local Anesthetics (e.g., lidocaine, mepivacaine, bupivacaine) | Additive blockade of sodium channels; additive systemic toxicity | Increased risk of LAST when total systemic exposure approaches toxic thresholds | Calculate combined dose against the lowest toxic threshold; avoid simultaneous use of multiple long-acting amides for prolonged blocks |
| Class I and III Antiarrhythmics (e.g., lidocaine, mexiletine, amiodarone, dronedarone) | Additive effects on cardiac sodium channels and conduction | Increased risk of bradycardia, atrioventricular block, and ventricular arrhythmias | Continuous ECG monitoring; consider dose reduction; avoid in patients with conduction disease |
Other Notable Interactions
| Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) | Modest reduction in CYP3A4-mediated metabolism of ropivacaine | Small increase in plasma ropivacaine levels; clinical significance generally limited | Routine monitoring; dose adjustment rarely required for single-shot techniques |
| CNS Depressants (opioids, benzodiazepines, general anesthetics) | Additive central nervous system and respiratory depression | Enhanced sedation and potential for respiratory depression, particularly with concurrent neuraxial opioids | Continuous respiratory and sedation monitoring; cautious titration of co-administered opioids |
| Anticoagulants and Antiplatelet Drugs (heparins, DOACs, warfarin, clopidogrel) | Increased bleeding risk at needle/catheter puncture site | Risk of spinal or epidural hematoma with potential permanent neurological damage | Strict adherence to ESRA/ASRA timing guidelines for neuraxial procedures |
| Antihypertensive Medications (ACE inhibitors, beta-blockers, calcium channel blockers) | Additive hypotensive effect with sympathetic blockade from epidural analgesia | Exaggerated hypotension, especially after initial loading doses | Preoperative optimization of blood pressure control; adequate intravenous hydration and readily available vasopressors |
| Herbal Supplements (e.g., St. John's wort, ginkgo biloba, garlic) | May alter bleeding risk or hepatic enzyme activity | Variable; may affect epidural hematoma risk or ropivacaine metabolism | Disclose all supplements; consider discontinuation before elective neuraxial anesthesia in consultation with the anesthesiologist |
A complete and current medication list, including over-the-counter products, herbal remedies, and recreational substances, should always be reviewed before regional anesthesia. Patients undergoing long-term therapy with strong CYP1A2 inhibitors deserve particular attention when a prolonged ropivacaine infusion is planned, as cumulative plasma concentrations can rise into the toxic range even at "normal" infusion rates.
What Is the Correct Dosage of Ropivakain Sintetica?
Quick Answer: Typical dosing of Ropivakain Sintetica 2 mg/ml for a continuous epidural infusion in an adult is 6–14 ml/hour (12–28 mg/hour) for postoperative pain, and 6–10 ml/hour for labor analgesia. Continuous peripheral nerve blocks typically use 5–10 ml/hour. The dose depends on the clinical setting, the block site, patient characteristics, and any co-administered opioid. Ropivacaine must be given only by qualified personnel.
Ropivakain Sintetica 2 mg/ml is administered exclusively by a qualified clinician, most commonly an anesthesiologist. The exact dose depends on the type of block, the site of injection, the desired intensity and duration of analgesia, the patient's physical status, and any concurrent analgesic medications. The doses below are typical adult ranges drawn from the current EMA Summary of Product Characteristics and major anesthesia textbooks; individual practice may vary and always takes precedence.
Adults
Continuous Epidural Infusion (Lumbar or Thoracic) – Postoperative Pain
Loading dose (if required): 10–20 ml (20–40 mg), given slowly and fractionated
Maintenance infusion: 6–14 ml/hour (12–28 mg/hour)
Patient-controlled epidural analgesia (PCEA): typical regimen 5–10 ml/hour background + 2–4 ml bolus every 10–30 minutes
Typical duration: up to 72 hours, sometimes longer under specialist supervision
Continuous Epidural Infusion – Labor Analgesia
Loading dose: 10–20 ml (20–40 mg), often combined with a small dose of fentanyl or sufentanil
Maintenance infusion: 6–10 ml/hour (12–20 mg/hour)
PCEA option: background 4–8 ml/hour + bolus 4–6 ml with a lockout of 10–20 minutes
Duration: throughout labor and delivery
Continuous Peripheral Nerve Block (e.g., brachial plexus, femoral, sciatic, adductor canal)
Infusion rate: 5–10 ml/hour (10–20 mg/hour), often with intermittent patient-controlled bolus
Maximum suggested duration: up to 48–72 hours of infusion; longer courses require specialist review
Field Block and Wound Infiltration
Volume: up to 100–200 ml per single administration, titrated to block extent
Total dose: should not exceed 200 mg in a 24-hour period for adult wound infiltration unless specifically directed by the anesthesiologist
The lowest effective concentration and dose should always be used. Continuous infusions should be titrated to clinical effect, with regular reassessment of pain relief, motor function, sensation, and signs of toxicity. In prolonged infusions, plasma ropivacaine concentrations rise gradually due to increased alpha-1-acid glycoprotein during the acute-phase response, though free (unbound) drug concentrations usually remain within safe limits in healthy adults.
Children and Adolescents
Ropivacaine 2 mg/ml is used in pediatric regional anesthesia, though specific approvals and dosing protocols vary by country and formulation. Pediatric dosing is strictly weight-based and should be determined only by pediatric anesthesiologists. Typical doses for continuous epidural infusion in infants and children range from 0.2 to 0.4 mg/kg/hour, with neonates requiring the lowest rates due to immature hepatic metabolism and reduced alpha-1-acid glycoprotein. Continuous peripheral nerve blocks in children typically use infusion rates of 0.1–0.3 ml/kg/hour. Always refer to local pediatric anesthesia guidelines.
Elderly Patients
Elderly patients may be more sensitive to the hemodynamic effects of epidural anesthesia, particularly hypotension, because of reduced sympathetic reserve. Hepatic metabolism of ropivacaine can also be slowed in advanced age, especially in frail patients with multiple comorbidities. Lower initial doses and infusion rates are often appropriate, combined with careful hemodynamic monitoring, adequate volume loading, and ready availability of vasopressors. A dose at the lower end of the recommended range (for example, 6–8 ml/hour for epidural infusion) is often a safe starting point.
Missed Dose / Infusion Interruption
Because Ropivakain Sintetica is given as a healthcare-controlled infusion or intermittent bolus rather than a self-administered oral tablet, the concept of a "missed dose" does not apply in the usual sense. If a scheduled bolus cannot be given on time, or if an infusion is temporarily stopped (for example, to check motor function or reposition a catheter), the clinical team will restart analgesia as soon as it is safe to do so. Patients should alert their nurse or doctor immediately if pain returns, if they notice weakness or numbness that was not present before, or if any side effect becomes troublesome.
Overdose
Because Ropivakain Sintetica is given exclusively by trained professionals in a monitored setting, overdose is rare. When it does occur, it is almost always the consequence of accidental intravascular injection or cumulative dosing beyond safe limits. The resulting condition, local anesthetic systemic toxicity (LAST), typically begins with central nervous system symptoms and can progress to cardiovascular collapse if not promptly recognized and treated.
- Early CNS signs: numbness around the mouth and tongue, metallic taste, tinnitus (ringing in the ears), blurred vision, lightheadedness, agitation, and muscle twitching
- Progressive CNS signs: generalized seizures, loss of consciousness, and respiratory arrest
- Cardiovascular signs: hypotension, bradycardia, atrioventricular block, ventricular arrhythmias, and in severe cases cardiac arrest
If LAST is suspected, the injection or infusion must be stopped immediately. Management follows published ASRA and ESRA LAST protocols: secure the airway, deliver 100% oxygen, control seizures (preferably with a benzodiazepine; avoid propofol in hemodynamically unstable patients), and administer intravenous 20% lipid emulsion as early as possible in cardiovascularly compromised patients. Advanced cardiac life support may be required, and prolonged resuscitation efforts are sometimes successful because lipid emulsion therapy can gradually restore myocardial function.
What Are the Side Effects of Ropivakain Sintetica?
Quick Answer: Like all medicines, Ropivakain Sintetica can cause side effects, although not everyone experiences them. The most common are hypotension (low blood pressure) and nausea, reported in more than 1 in 10 patients. Most adverse effects stem from the regional block itself and resolve as the block wears off. Serious but rare adverse effects include local anesthetic systemic toxicity, spinal or epidural hematoma, and permanent neurological injury.
Many of the effects seen with ropivacaine are shared with other long-acting local anesthetics and reflect the normal physiology of regional blockade rather than direct drug toxicity. Hypotension, for example, is almost entirely due to sympathetic blockade and venous pooling in the lower body during epidural analgesia, not to a direct effect of ropivacaine on the heart. Other effects, such as nausea and urinary retention, are predictable consequences of the block and are routinely managed by the anesthesia and nursing team.
Serious allergic reactions (anaphylaxis) are very rare but can occur. Symptoms include sudden itching, generalized flushing, swelling of the face or throat, difficulty breathing, wheezing, chest tightness, nausea, vomiting, a sudden drop in blood pressure, or loss of consciousness. Tell your team immediately if you notice new or worsening back pain, a severe headache that does not respond to usual measures, persistent weakness or numbness beyond the expected duration of the block, or loss of bladder or bowel control — these may indicate a rare but serious complication such as an epidural hematoma or abscess that requires urgent treatment.
Very Common
May affect more than 1 in 10 patients
- Hypotension (low blood pressure)
- Nausea
Common
May affect up to 1 in 10 patients
- Bradycardia (slow heart rate)
- Tachycardia (fast heart rate)
- Hypertension (raised blood pressure)
- Back pain
- Headache
- Dizziness
- Paraesthesia (tingling or abnormal sensations)
- Vomiting
- Urinary retention (difficulty passing urine)
- Fever and shivering
Uncommon
May affect up to 1 in 100 patients
- Anxiety, restlessness
- Hypoaesthesia (reduced sensation)
- Syncope (fainting)
- Breathing difficulty (dyspnoea)
- Hypothermia
- Symptoms of local anesthetic systemic toxicity (numbness around the mouth, tinnitus, metallic taste, muscle twitching, seizures)
Rare
May affect up to 1 in 1,000 patients
- Cardiac arrest
- Severe cardiac arrhythmias (ventricular tachycardia, ventricular fibrillation)
- Anaphylactic and anaphylactoid reactions
- Neuropathy and other nerve injuries, including spinal cord lesions
- Arachnoiditis
- Permanent or long-lasting sensory or motor deficits
- Epidural or spinal hematoma or abscess, particularly in patients with coagulopathy or infection
Frequency Not Known
Reported post-marketing; frequency cannot be estimated from available data
- Angioedema
- Urticaria (hives)
- Dyskinesia
- Chondrolysis (cartilage damage) associated with prolonged intra-articular infusion of local anesthetics – intra-articular infusion is NOT recommended
Hypotension and bradycardia are most likely in patients with pre-existing hypovolemia, cardiovascular disease, or autonomic dysfunction, and are usually managed with intravenous fluids, vasopressors (such as ephedrine or phenylephrine), and, when needed, atropine. These responses are transient and do not typically require discontinuation of the block.
Urinary retention is common during epidural analgesia because the sympathetic and parasympathetic fibers controlling the bladder are blocked along with sensory fibers. Bladder scanning and, if necessary, intermittent catheterization manage this safely until the block wears off. Back pain is common but usually mild and reflects the needle insertion itself rather than any drug effect.
Persistent neurological deficits after epidural or peripheral nerve block with ropivacaine are rare but important to recognize early. Any new weakness, sensory loss, or bowel/bladder dysfunction that persists beyond the expected duration of the block should prompt urgent neurological evaluation and imaging, as early diagnosis of complications such as epidural hematoma or abscess is critical to preserving neurological function.
If you experience any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side effects not listed here. You can also report side effects directly via your national pharmacovigilance system (for example, the MHRA Yellow Card scheme in the United Kingdom, MedWatch in the United States, or the EudraVigilance network in the European Union). By reporting side effects, you help provide more information on the safety of this medicine.
How Should Ropivakain Sintetica Be Stored?
Quick Answer: Ropivakain Sintetica should be stored below 30°C in its original packaging to protect from light, and must not be frozen. Once opened, the solution is intended for immediate single use; any unused portion should be discarded according to local waste regulations. Do not use the product after the expiry date printed on the container.
Correct storage is essential to preserve the stability, sterility, and potency of the solution. Because Ropivakain Sintetica is a hospital-administered medicine, storage and disposal are usually managed by pharmacy and clinical staff, but the key principles are relevant whenever healthcare providers handle the product:
- Temperature: Store below 30°C (86°F) unless otherwise specified on the container. Do not refrigerate and do not freeze — freezing can precipitate the active ingredient and alter the solution's physicochemical properties.
- Light protection: Keep containers in the outer carton until use to protect from light.
- Integrity of packaging: Inspect each bag or bottle before use. Do not use if the container is damaged, if the solution is cloudy or discolored, or if particulate matter is visible.
- Single use: Ropivakain Sintetica is for single use. Any unused solution remaining after use must be discarded and never retained for subsequent administration.
- Expiry date: Do not use after the expiry date printed on the label. The expiry date refers to the last day of the stated month.
- Compatibility: The manufacturer provides specific guidance on compatibility with other drugs for epidural or perineural infusion (for example, fentanyl or sufentanil added to the infusion bag). Mixtures should only be prepared in accordance with this guidance, ideally by a sterile compounding pharmacy.
- Waste disposal: Medicines must not be disposed of via household waste or wastewater. Unused product should be returned to the pharmacy or disposed of according to local pharmaceutical waste regulations to protect the environment.
Keep all medicines out of the sight and reach of children. Although Ropivakain Sintetica is not dispensed for home use, general medication safety principles still apply wherever the product is stored.
What Does Ropivakain Sintetica Contain?
Quick Answer: Each milliliter of Ropivakain Sintetica 2 mg/ml solution for infusion contains 2 mg of ropivacaine hydrochloride (as monohydrate) as the active substance. The solution also contains sodium chloride to maintain isotonicity, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injections. It is preservative-free.
Active Substance
The active pharmaceutical ingredient is ropivacaine hydrochloride. Each ml of solution contains 2 mg of ropivacaine hydrochloride (equivalent to the free base plus the hydrochloride salt), typically supplied as ropivacaine hydrochloride monohydrate. Typical presentations include 100 ml and 200 ml infusion bags or bottles (200 mg and 400 mg total ropivacaine content, respectively).
Ropivacaine (chemical name: (S)-1-propyl-2',6'-pipecoloxylidide hydrochloride) is the pure S-enantiomer of a propyl-substituted pipecoloxylidide local anesthetic. It was specifically developed as a single enantiomer to exploit the improved cardiac safety margin associated with S-enantiomers of the pipecoloxylidide class. The molecular weight of ropivacaine hydrochloride monohydrate is 328.88 g/mol.
Inactive Ingredients (Excipients)
- Sodium chloride: maintains the solution isotonic with physiological fluids, which is essential for epidural and perineural administration.
- Sodium hydroxide and/or hydrochloric acid: used in small quantities to adjust the pH of the solution to approximately 4.0–6.0, the pH range that maximizes the chemical stability of ropivacaine hydrochloride.
- Water for injections: the sterile solvent used to prepare the solution.
Ropivakain Sintetica 2 mg/ml is preservative-free. The absence of antimicrobial preservatives, bisulfites, and EDTA makes the formulation suitable for epidural, perineural, and other regional anesthetic techniques where neurotoxicity of excipients would be unacceptable. This also means that each container is intended for single use and cannot be re-entered.
Appearance and Packaging
Ropivakain Sintetica 2 mg/ml is a clear, colorless, sterile solution for infusion. It is commonly supplied in polypropylene infusion bags or glass bottles of 100 ml and 200 ml, individually packed with an outer carton to protect from light. Presentations and exact pack sizes may vary by country; consult the local summary of product characteristics or package leaflet for details.
Frequently Asked Questions About Ropivakain Sintetica
Ropivakain Sintetica 2 mg/ml is a long-acting amide local anesthetic used for continuous epidural analgesia, continuous peripheral nerve blocks, and field block. At this concentration it is optimal for acute pain management, especially postoperative pain after major surgery and labor pain during childbirth. It provides effective analgesia with minimal motor blockade, allowing patients to remain comfortable while still being able to move their legs.
As a continuous infusion, ropivacaine 2 mg/ml provides analgesia for as long as the infusion is maintained — typically 24–72 hours postoperatively and throughout labor. After a single bolus, sensory block from ropivacaine 2 mg/ml lasts approximately 2–6 hours depending on the site and volume injected. Motor block at this low concentration is usually minimal and shorter in duration than sensory block.
At equipotent doses, ropivacaine has a better cardiac safety profile than racemic bupivacaine. As the pure S-enantiomer, it has less affinity for cardiac sodium channels and causes less myocardial depression, which is why it has largely replaced bupivacaine in settings where large-volume or long-duration continuous infusions are needed. Clinical studies and case series also suggest that accidental intravascular injection of ropivacaine is less likely to produce the resistant ventricular arrhythmias historically associated with bupivacaine toxicity. It is still a potent local anesthetic, however, and must always be used under appropriate safety precautions.
Yes. Ropivacaine 2 mg/ml is one of the most widely used local anesthetics for epidural labor analgesia, often combined with a small dose of a lipophilic opioid such as fentanyl or sufentanil. It provides excellent pain relief during contractions while preserving enough motor function to enable upright positions and, in some centers, supported ambulation. Higher concentrations (7.5 mg/ml or 10 mg/ml) are used for surgical anesthesia during cesarean delivery. Paracervical block with ropivacaine, however, is contraindicated in obstetrics due to the risk of fetal bradycardia.
Tell your medical team immediately if you experience any of the following: numbness or tingling around your mouth, a metallic taste, ringing in the ears, dizziness, visual disturbances, muscle twitching, palpitations, chest pain, severe back pain, a severe headache that is worse when sitting up, new weakness in your legs, or loss of bladder or bowel control. These can be early signs of local anesthetic toxicity or a neurological complication. Routine checks of pain, sensation, movement, blood pressure, heart rate, and catheter site will be performed regularly by nursing and medical staff.
Ropivacaine 2 mg/ml is designed to produce minimal motor block, so carefully selected patients in dedicated obstetric units may be able to walk with support during labor (sometimes called a "walking epidural"). After major surgery, however, walking is usually delayed by the surgery itself rather than by the epidural. Eating and drinking depend on your surgery, the opioid component of your analgesia, and your medical team's advice. Always ask your nurse or doctor before getting out of bed or eating while an epidural is running.
References
- European Medicines Agency (EMA). Ropivacaine Summary of Product Characteristics. Sintetica SA. Current revision.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- McClellan KJ, Faulds D. Ropivacaine: an update of its use in regional anaesthesia. Drugs. 2000;60(5):1065-1093.
- Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth. 2011;55(2):104-110.
- Graf BM, Abraham I, Eberbach N, et al. Differences in cardiotoxicity of bupivacaine and ropivacaine are the result of physicochemical and stereoselective properties. Anesthesiology. 2002;96(6):1427-1434.
- Knudsen K, Beckman Suurküla M, Blomberg S, Sjövall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth. 1997;78(5):507-514.
- Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity Checklist: 2020 version. Reg Anesth Pain Med. 2021;46(1):81-82.
- El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local Reg Anesth. 2018;11:35-44.
- Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: ASRA Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018;43(3):263-309.
- Kinsella SM, Carvalho B, Dyer RA, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia. 2018;73(1):71-92.
- Hadzic A (ed). Hadzic's Textbook of Regional Anesthesia and Acute Pain Management. 2nd ed. New York: McGraw-Hill Education; 2017.
- British National Formulary (BNF). Ropivacaine hydrochloride. National Institute for Health and Care Excellence (NICE). 2025.
- U.S. Food and Drug Administration (FDA). Naropin (ropivacaine hydrochloride injection) Prescribing Information. Current revision.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Anesthesiology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, ASRA, and ESRA guidelines
Evidence Standard
GRADE Framework – Level 1A evidence from systematic reviews and randomized controlled trials
Editorial Independence
No pharmaceutical funding. Independent, evidence-based content with no commercial influence.
This article was written by medical professionals and reviewed according to international clinical guidelines. Last medical review: . For more about our editorial process, see our Medical Team and Editorial Standards pages.